MX2017001302A - Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. - Google Patents
Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk.Info
- Publication number
- MX2017001302A MX2017001302A MX2017001302A MX2017001302A MX2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A MX 2017001302 A MX2017001302 A MX 2017001302A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- dlbcl
- biomarkers
- biomarker genes
- preach
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462032430P | 2014-08-01 | 2014-08-01 | |
| US201562119668P | 2015-02-23 | 2015-02-23 | |
| US201562127484P | 2015-03-03 | 2015-03-03 | |
| PCT/US2015/043300 WO2016019341A1 (en) | 2014-08-01 | 2015-07-31 | Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001302A true MX2017001302A (es) | 2017-10-11 |
Family
ID=55179406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001302A MX2017001302A (es) | 2014-08-01 | 2015-07-31 | Biomarcadores para predecir la respuesta del dlbcl al tratamiento con un inhibidor de la btk. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160032404A1 (enExample) |
| EP (1) | EP3185870A4 (enExample) |
| JP (1) | JP2017523188A (enExample) |
| KR (1) | KR20170042614A (enExample) |
| CN (1) | CN106714804A (enExample) |
| AU (1) | AU2015296010A1 (enExample) |
| BR (1) | BR112017001677A2 (enExample) |
| CA (1) | CA2955744A1 (enExample) |
| IL (1) | IL250221A0 (enExample) |
| MX (1) | MX2017001302A (enExample) |
| RU (1) | RU2017106794A (enExample) |
| SG (1) | SG11201700774UA (enExample) |
| WO (1) | WO2016019341A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS53350B (sr) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | Supstituisana jedinjenja imidazo[1,2-b]piridazina kao inhibitori trk kinaze |
| HRP20140309T1 (hr) | 2008-10-22 | 2014-05-09 | Array Biopharma, Inc. | SUPSTITUIRANI SPOJEVI PIRAZOLO[1,5-a]PIRIMIDINA KAO INHIBITORI TRK KINAZE |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| KR102015402B1 (ko) | 2010-05-20 | 2019-08-28 | 어레이 바이오파마 인크. | Trk 키나제 저해제로서의 매크로시클릭 화합물 |
| NZ772688A (en) | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
| WO2016071770A2 (en) * | 2014-11-05 | 2016-05-12 | Janssen Pharmaceutica Nv | Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same |
| JP6914834B2 (ja) | 2014-11-16 | 2021-08-04 | アレイ バイオファーマ インコーポレイテッド | （Ｓ）−Ｎ−（５−（（Ｒ）−２−（２，５−ジフルオロフェニル）−ピロリジン−１−イル）−ピラゾロ［１，５−ａ］ピリミジン−３−イル）−３−ヒドロキシピロリジン−１−カルボキサミド硫酸水素塩の結晶形 |
| PL3892302T3 (pl) | 2015-04-06 | 2024-03-11 | Janssen Pharmaceutica Nv | Kompozycje zawierające ibrutynib |
| TN2018000138A1 (en) | 2015-10-26 | 2019-10-04 | Array Biopharma Inc | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| AU2017246554B2 (en) | 2016-04-04 | 2022-08-18 | Loxo Oncology, Inc. | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| KR102566858B1 (ko) | 2016-05-18 | 2023-08-11 | 어레이 바이오파마 인크. | (s)-n-(5-((r)-2-(2,5-디플루오로페닐)피롤리딘-1-일)-피라졸로[1,5-a]피리미딘-3-일)-3-히드록시피롤리딘-1-카르복사미드의 제조 방법 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| US11085039B2 (en) | 2016-12-12 | 2021-08-10 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US11473081B2 (en) | 2016-12-12 | 2022-10-18 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| US11156626B2 (en) | 2016-12-30 | 2021-10-26 | xCella Biosciences, Inc. | Multi-stage sample recovery system |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| EP3612192A4 (en) * | 2017-06-08 | 2020-05-27 | Enlivex Therapeutics Ltd. | THERAPEUTIC APOPTOTIC CELLS FOR CANCER THERAPY |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| KR20250125432A (ko) * | 2018-06-15 | 2025-08-21 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| GB2577909B (en) * | 2018-10-10 | 2020-11-18 | Symetrica Ltd | Gamma-ray spectrum classification |
| US20200171034A1 (en) * | 2018-11-30 | 2020-06-04 | Janssen Biotech, Inc. | Methods Of Treating Follicular Lymphoma |
| EP3890876B1 (en) | 2018-12-06 | 2024-05-01 | Xcella Biosciences, Inc. | Lateral loading of microcapillary arrays |
| WO2021087044A1 (en) * | 2019-10-30 | 2021-05-06 | Celgene Corporation | Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma |
| WO2022169731A1 (en) * | 2021-02-03 | 2022-08-11 | Curis Inc. | Biomarkers for fimepinostat therapy |
| BR112023025459A2 (pt) | 2021-06-04 | 2024-02-27 | Janssen Pharmaceutica Nv | Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos |
| WO2023275330A1 (en) * | 2021-06-30 | 2023-01-05 | Janssen Pharmaceutica Nv | Treatments for diffuse large b-cell lymphoma |
| CA3223610A1 (en) * | 2021-06-30 | 2023-01-05 | Janssen Pharmaceutica Nv | Inhibitors of bruton's tyrosine kinase and methods of their use |
| JP7423090B2 (ja) * | 2022-04-07 | 2024-01-29 | 学校法人藤田学園 | 不明熱患者のｂ細胞リンパ腫診断補助キットおよび情報提供方法 |
| CN121969770A (zh) * | 2023-10-09 | 2026-05-01 | 百时美施贵宝公司 | 预测淋巴瘤对药物的反应性的方法以及治疗淋巴瘤的方法 |
| JP7696987B1 (ja) | 2023-12-22 | 2025-06-23 | 東洋鋼鈑株式会社 | 遺伝子変異を検出する方法 |
| JP7698850B1 (ja) * | 2023-12-22 | 2025-06-26 | 東洋鋼鈑株式会社 | 遺伝子変異評価用キット |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ772688A (en) * | 2010-06-03 | 2022-09-30 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| US20130102477A1 (en) * | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| CN110801454A (zh) * | 2011-10-19 | 2020-02-18 | 药品循环有限责任公司 | 布鲁顿酪氨酸激酶(btk)抑制剂的用途 |
| JP2014532658A (ja) * | 2011-10-28 | 2014-12-08 | セルジーン アヴィロミクス リサーチ， インコーポレイテッド | ブルトン型チロシンキナーゼ疾患または障害を治療する方法 |
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| AU2013293087B2 (en) * | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
| WO2014110114A1 (en) * | 2013-01-10 | 2014-07-17 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
-
2015
- 2015-07-31 SG SG11201700774UA patent/SG11201700774UA/en unknown
- 2015-07-31 CA CA2955744A patent/CA2955744A1/en not_active Abandoned
- 2015-07-31 WO PCT/US2015/043300 patent/WO2016019341A1/en not_active Ceased
- 2015-07-31 JP JP2017504752A patent/JP2017523188A/ja active Pending
- 2015-07-31 US US14/815,921 patent/US20160032404A1/en not_active Abandoned
- 2015-07-31 EP EP15828160.0A patent/EP3185870A4/en not_active Withdrawn
- 2015-07-31 RU RU2017106794A patent/RU2017106794A/ru not_active Application Discontinuation
- 2015-07-31 KR KR1020177005365A patent/KR20170042614A/ko not_active Withdrawn
- 2015-07-31 AU AU2015296010A patent/AU2015296010A1/en not_active Abandoned
- 2015-07-31 CN CN201580049596.7A patent/CN106714804A/zh active Pending
- 2015-07-31 MX MX2017001302A patent/MX2017001302A/es unknown
- 2015-07-31 BR BR112017001677-0A patent/BR112017001677A2/pt not_active Application Discontinuation
-
2017
- 2017-01-22 IL IL250221A patent/IL250221A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20160032404A1 (en) | 2016-02-04 |
| BR112017001677A2 (pt) | 2018-07-17 |
| CA2955744A1 (en) | 2016-02-04 |
| IL250221A0 (en) | 2017-03-30 |
| AU2015296010A1 (en) | 2017-02-02 |
| RU2017106794A (ru) | 2018-09-03 |
| JP2017523188A (ja) | 2017-08-17 |
| CN106714804A (zh) | 2017-05-24 |
| SG11201700774UA (en) | 2017-02-27 |
| EP3185870A4 (en) | 2018-06-20 |
| EP3185870A1 (en) | 2017-07-05 |
| KR20170042614A (ko) | 2017-04-19 |
| RU2017106794A3 (enExample) | 2019-02-27 |
| WO2016019341A1 (en) | 2016-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| EP4321866A3 (en) | Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers | |
| MX2018005070A (es) | Composición para el tratamiento de cáncer con expresión del igf-1r. | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| CL2018000596A1 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| PE20210650A1 (es) | Terapia basada en anticuerpos de amiloidosis por transtiretina (ttr) y anticuerpos derivados de humanos de la misma | |
| EP4060048A3 (en) | Non-invasive diagnostic method for diagnosing bladder cancer | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| CL2019002438A1 (es) | Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5. | |
| PE20160192A1 (es) | Composiciones y metodo para tratar condiciones asociadas con el complemento | |
| MX375933B (es) | Uso medico de compuestos de artemisinina y agonistas de gefirina. | |
| BR112018009463A2 (pt) | ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia | |
| MX2022001293A (es) | Receptores de antigeno quimerico que se dirigen al antigeno de maduracion de celulas b y sus usos. | |
| MX2018001697A (es) | Método para la cuantificación de los miembros del filogrupo i y/o del filogrupo ii de faecalibacterium prausnitzii y el uso de los mismos como biomarcadores. | |
| MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
| BR112016026730A2 (pt) | métodos de caracterização e tratamento de leucemia mieloide aguda | |
| CL2020001936A1 (es) | Métodos para el tratamiento de la atrofía muscular espinal. | |
| MX2016009991A (es) | Nuevo anticuerpo anti-dengue de espectro completo. | |
| MX2017008096A (es) | Pestivirus. | |
| MX2017006075A (es) | Biomarcadores para la progresion de enfermedades en melanoma. | |
| BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo | |
| BR112016019588A2 (pt) | produto de ativação de mmp-8, e, método de determinação da ativação da mmp-8 em uma amostra | |
| BR112017011026A2 (pt) | métodos analíticos e arranjos para uso nos mesmos | |
| MX2022003719A (es) | Anticuerpos anti-il-27 y sus usos. |